CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Cellectar Biosciences, Inc. - CLRB CFD

2.60
4.42%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.04
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 2.49
Open* 2.43
1-Year Change* 44.64%
Day's Range* 2.43 - 2.6
52 wk Range 1.25-3.15
Average Volume (10 days) 201.46K
Average Volume (3 months) 15.22M
Market Cap 26.30M
P/E Ratio -100.00K
Shares Outstanding 12.29M
Revenue N/A
EPS -3.44
Dividend (Yield %) N/A
Beta 1.05
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 7, 2023 2.49 0.10 4.18% 2.39 2.54 2.35
Dec 6, 2023 2.52 0.03 1.20% 2.49 2.57 2.41
Dec 5, 2023 2.54 0.15 6.28% 2.39 2.58 2.39
Dec 4, 2023 2.49 -0.02 -0.80% 2.51 2.54 2.39
Dec 1, 2023 2.54 0.12 4.96% 2.42 2.54 2.38
Nov 30, 2023 2.42 0.28 13.08% 2.14 2.47 2.14
Nov 29, 2023 2.22 0.05 2.30% 2.17 2.26 2.12
Nov 28, 2023 2.19 0.11 5.29% 2.08 2.22 2.08
Nov 27, 2023 2.13 0.04 1.91% 2.09 2.16 2.06
Nov 24, 2023 2.06 -0.04 -1.90% 2.10 2.17 2.06
Nov 22, 2023 2.17 0.08 3.83% 2.09 2.20 2.05
Nov 21, 2023 2.11 -0.03 -1.40% 2.14 2.19 2.10
Nov 20, 2023 2.15 0.16 8.04% 1.99 2.21 1.99
Nov 17, 2023 2.04 0.12 6.25% 1.92 2.08 1.92
Nov 16, 2023 1.97 0.00 0.00% 1.97 1.99 1.87
Nov 15, 2023 1.97 0.01 0.51% 1.96 2.03 1.94
Nov 14, 2023 1.99 -0.01 -0.50% 2.00 2.07 1.96
Nov 13, 2023 2.03 0.11 5.73% 1.92 2.06 1.86
Nov 10, 2023 1.93 0.04 2.12% 1.89 1.96 1.85
Nov 9, 2023 1.94 -0.10 -4.90% 2.04 2.09 1.87

Cellectar Biosciences, Inc. Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Cellectar Biosciences Inc Earnings Release
Q4 2023 Cellectar Biosciences Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 28.8138 24.1313 15.1051 14.1786 13.3308
Selling/General/Admin. Expenses, Total 9.59417 6.54481 5.14967 5.18257 4.82007
Research & Development 19.2196 17.5865 10.1407 8.99606 6.83523
Unusual Expense (Income) 0 -0.18528 0 1.67546
Operating Income -28.8138 -24.1313 -15.1051 -14.1786 -13.3308
Interest Income (Expense), Net Non-Operating 0.15252 0.00228 0.0109 0.08571 0.09174
Net Income Before Taxes -28.6612 -24.1224 -15.0942 -14.0929 -13.239
Net Income After Taxes -28.6012 -24.1224 -15.0942 -14.0929 -13.239
Net Income Before Extra. Items -28.6012 -24.1224 -15.0942 -14.0929 -13.239
Net Income -28.6012 -24.1224 -15.0942 -14.0929 -13.239
Income Available to Common Excl. Extra. Items -28.6012 -24.1224 -15.0942 -14.0929 -15.4808
Income Available to Common Incl. Extra. Items -28.6012 -24.1224 -15.0942 -14.0929 -15.4808
Diluted Net Income -28.6012 -24.1224 -15.0942 -14.0929 -15.4808
Diluted Weighted Average Shares 7.05567 5.55157 1.98127 0.76751 0.2962
Diluted EPS Excluding Extraordinary Items -4.05366 -4.34514 -7.61845 -18.3619 -52.2653
Diluted Normalized EPS -4.05366 -4.34514 -7.71196 -18.3619 -46.6087
Total Adjustments to Net Income 0 -2.2418
Revenue 0
Other, Net 0 0.00663
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 8.294 8.7053 7.42254 7.81549 7.43552
Selling/General/Admin. Expenses, Total 1.98557 2.05121 1.96878 2.4353 2.93687
Research & Development 6.30843 6.65409 5.45376 5.38019 4.49866
Operating Income -8.294 -8.7053 -7.42254 -7.81549 -7.43552
Interest Income (Expense), Net Non-Operating 0.07278 0.12403 0.14744 0.00416 0.00048
Net Income Before Taxes -8.22122 -8.58127 -7.27509 -7.81132 -7.43504
Net Income After Taxes -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
Net Income Before Extra. Items -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
Net Income -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
Income Available to Common Excl. Extra. Items -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
Income Available to Common Incl. Extra. Items -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
Diluted Net Income -8.22122 -8.58127 -7.21509 -7.81132 -7.43504
Diluted Weighted Average Shares 11.2612 11.2612 9.89229 6.11012 6.11012
Diluted EPS Excluding Extraordinary Items -0.73005 -0.76202 -0.72937 -1.27842 -1.21684
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.73005 -0.76202 -0.72937 -1.27842 -1.21684
Unusual Expense (Income)
Other, Net
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 20.5296 36.5715 57.9398 11.3857 13.9518
Cash and Short Term Investments 19.8664 35.704 57.1654 10.6147 13.2556
Cash & Equivalents 19.8664 35.704 57.1654 10.6147 13.2556
Prepaid Expenses 0.66324 0.86749 0.77443 0.77095 0.64122
Other Current Assets, Total 0 0.055
Total Assets 21.5898 37.2018 58.6594 12.2508 15.0541
Property/Plant/Equipment, Total - Net 0.97898 0.54914 0.63835 0.78392 0.54334
Property/Plant/Equipment, Total - Gross 1.67151 1.09391 1.04202 1.09333
Accumulated Depreciation, Total -0.69253 -0.54478 -0.40367 -0.30941
Goodwill, Net 0
Other Long Term Assets, Total 0.08121 0.08121 0.08121 0.08121 0.55891
Total Current Liabilities 5.52929 3.99036 3.5631 2.76976 1.62212
Payable/Accrued 1.63744 1.88091 0.7872 0.71987 1.54382
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.00221
Other Current Liabilities, Total 0 0.07609
Total Liabilities 6.08227 4.15666 3.86484 3.1914 1.79312
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Capital Lease Obligations 0
Other Liabilities, Total 0.55298 0.16629 0.30174 0.42164 0.171
Total Equity 15.5075 33.0452 54.7945 9.05941 13.261
Redeemable Preferred Stock 1.38202 1.38202 20.0359 1.1482 2.52605
Common Stock 0.00009 0.00061 0.00045 0.00009 0.00005
Additional Paid-In Capital 193.624 182.56 161.534 119.592 108.323
Retained Earnings (Accumulated Deficit) -179.499 -150.898 -126.775 -111.681 -97.5883
Total Liabilities & Shareholders’ Equity 21.5898 37.2018 58.6594 12.2508 15.0541
Total Common Shares Outstanding 9.38527 6.11013 4.54427 0.93867 0.47324
Total Preferred Shares Outstanding 0.00011 0.00011 0.00173 0.00022 0
Accounts Payable 2.558 1.415 1.429 1.278
Accrued Expenses 1.33385 0.69445 1.3469 0.77189
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 20.1099 5.60965 13.8464 20.5296 18.7613
Cash and Short Term Investments 18.9864 5.15297 12.6827 19.8664 17.7853
Cash & Equivalents 18.9864 5.15297 12.6827 19.8664 17.7853
Prepaid Expenses 1.12347 0.45668 1.16375 0.66324 0.97594
Total Assets 21.5508 6.50917 14.8385 21.5898 19.3195
Property/Plant/Equipment, Total - Net 1.41108 0.86973 0.92259 0.97898 0.47704
Other Long Term Assets, Total 0.02978 0.02978 0.06943 0.08121 0.08121
Total Current Liabilities 16.4708 6.44531 6.95565 5.52929 6.51524
Payable/Accrued 7.81459 6.39167 6.90455 5.47844 6.36704
Accrued Expenses 0.05626 0.05364 0.05111 0.05085 0.1482
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 16.9836 6.97617 7.504 6.08227 6.569
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.51275 0.53086 0.54834 0.55298 0.05377
Total Equity 4.56716 -0.467 7.33446 15.5075 12.7505
Redeemable Preferred Stock 19.302 1.38202 1.38202 1.38202 1.38202
Common Stock 0.0001 0.0001 0.0001 0.00009 0.00006
Additional Paid-In Capital 195.299 194.452 194.033 193.624 183.652
Retained Earnings (Accumulated Deficit) -210.034 -196.302 -188.08 -179.499 -172.284
Total Liabilities & Shareholders’ Equity 21.5508 6.50917 14.8385 21.5898 19.3195
Total Common Shares Outstanding 9.91838 9.74051 9.74051 9.38527 6.11012
Total Preferred Shares Outstanding 0.00011 0.00011 0.00011 0.00011 0.00011
Other Current Liabilities, Total 8.6
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -28.6012 -24.1224 -15.0942 -14.0929 -13.239
Cash From Operating Activities -25.2223 -22.5688 -13.9327 -11.6937 -11.4421
Cash From Operating Activities 0.14844 0.14992 0.14145 0.1328 0.08227
Non-Cash Items 1.54678 1.20485 0.34874 0.88035 2.28372
Cash Interest Paid 0 0.00158 0.00088 0
Changes in Working Capital 1.68374 0.19876 0.67124 1.38605 -0.56905
Cash From Investing Activities -0.22597 -0.14136 -0.06235 -0.02454 -0.32999
Capital Expenditures -0.22597 -0.14136 -0.06235 -0.02454 -0.38499
Cash From Financing Activities 9.61066 1.2488 60.5457 9.02236 15.0213
Financing Cash Flow Items 0 -0.00076
Issuance (Retirement) of Stock, Net 9.61066 1.2488 60.3618 9.02457 15.0251
Issuance (Retirement) of Debt, Net 0 0.184 -0.00221 -0.00304
Net Change in Cash -15.8376 -21.4614 46.5507 -2.69589 3.2492
Other Investing Cash Flow Items, Total 0 0.055
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -8.58127 -28.6012 -21.3862 -13.5748 -6.1398
Cash From Operating Activities -7.18367 -25.2223 -17.8105 -10.7974 -5.03978
Cash From Operating Activities 0.04256 0.14844 0.11028 0.07732 0.04342
Non-Cash Items 0.42204 1.54678 1.16145 0.77068 0.32516
Cash Interest Paid
Changes in Working Capital 0.93301 1.68374 2.3039 1.92949 0.73143
Cash From Financing Activities 0 9.61066 0 0 0
Issuance (Retirement) of Stock, Net 0 9.61066 0 0 0
Net Change in Cash -7.18367 -15.8376 -17.9186 -10.8984 -5.06985
Cash From Investing Activities 0 -0.22597 -0.10812 -0.10105 -0.03007
Capital Expenditures 0 -0.22597 -0.10812 -0.10105 -0.03007
Issuance (Retirement) of Debt, Net
Financing Cash Flow Items

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cellectar Biosciences, Inc. Company profile

About Cellectar Biosciences Inc

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. Through its Phospholipid drug conjugate (PDC) deliver platform the Company is focused on to develop PDCs that are designed to target cancer cells. The Company's pipeline consists of clinical and pre-clinical product candidates. Its lead PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells. PDC product candidates also include CLR 1900, 2000 and 12120 series of conjugated compounds, which is being researched independently and through partnerships. The CLR 1900 Series is being targeted for solid tumors with a payload that inhibits mitosis a pathway for treating cancers. CLR 2000 Series is a collaborative PDC program with Avicenna Oncology. CLR 12120 Series is a collaborative PDC program with Orano Med for the development of PDCs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cellectar Biosciences Inc revenues was not reported. Net loss increased 60% to $24.1M. Higher net loss reflects Reaserch and development increase of 74% to $17.5M (expense), General and administrative increase of 16% to $5.5M (expense), General and administrative increase from $395K to $1M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.43.

Equity composition

Common Stock $.00153 Par, 03/11, 150M auth., 731,576 issd. Insiders own 47.57%. Preferred Stock $.00001 Par, 7K auth., Ser.C 204 issd. Sr E $0.00001 Par, 408.264045 issd., 04/11, 1-for-153 reverse split. 06/14, 1-for-20 Reverse stock split. 03/16 1-for-10 Reverse stock split.

Industry: Pharmaceuticals (NEC)

100 Campus Drive
FLORHAM PARK
NEW JERSEY 07932
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

Oil - Crude

71.41 Price
+2.320% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

16,080.90 Price
+0.500% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,004.85 Price
-1.180% 1D Chg, %
Long position overnight fee -0.0198%
Short position overnight fee 0.0116%
Overnight fee time 22:00 (UTC)
Spread 0.50

XRP/USD

0.68 Price
+3.860% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading